The Deal
Saturday, November 21, 
9:38 pm

Bausch & Lomb responds to AMO

  Share     E-Mail    Discussion (1)     Print Story

On Monday morning, Bausch & Lomb agreed to allow rival Advanced Medical Optics Inc. to provide certain information about its $4.23 billion takeover offer to some of AMO's large shareholders.

This came in reply to Friday's letter from AMO, which offered several proposals to make their rival bid more appealing than the $3.5 billion, $65 per share, cash take-private agreement with Warburg Pincus. On Friday, AMO offerred to have its shareholders vote on the proposed deal before Bausch & Lomb investors weigh the Warburg Pincus offer. Advanced Medical also offered to pay a $50 million reverse termination fee if its investors voted against the deal.

Advanced Medical's offer has been opposed by its third-largest shareholder, ValueAct Capital. And as The Deal's Scott Stuart writes in today's Arbitrage column, arbs think ValueAct is not alone in its opposition.

Among the details AMO wants to be free to discuss is its plan for potential divestitures as well as the deal's potential positive boost to earnings.

Bausch & Lomb asked Advanced Medical to provide "concrete, credible evidence" of its ability to secure approval from its stockholders no later than 12 p.m. Aug 3 - Tom Groppe

See today's Arbitrage column on TheDeal.com

Continue reading below

Also on Dealscape





Comments

From: Scott,

Based on this latest news, AMO may still have a chance at B&L, but I think WP may still have the advantage. Some of the ties between B&L and WP execs are pretty strong, which may be a lot of why AMO seems to be having such a hard time. (NewsVisual has an article referring to some of these connections: http://www.newsvisual.com/newsvisual/2007/07/bausch-lomb-tak.html )


Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Avaya Inc.'s Mohamad Ali on the company's next target.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


Industry Insight

Easing the stress of distressed M&A

Corporate buyers face numerous complexities when trying to identify the right moment to purchase a distressed asset.


Editor's Note

Editor's letter: Nov. 16, 2009

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.